To the best of our knowledge, no previous studies were conducted to assess the diagnostic accuracy of the combined use of BAP1, EZH2 and Survivin in discriminating pleural epithelioid mesothelioma from reactive mesothelial hyperplasia. This evidence concerns the gene EZH2 and pleural epithelioid mesothelioma.